CAR T cell News and Research

RSS

CAR T-cell therapy successfully treats rare autoimmune disease of the peripheral nervous system

Physicians from Bochum have used a cancer treatment method to treat severe autoimmune diseases.

18 Jun 2025

Deep B cell depletion offers new hope for rheumatologic and musculoskeletal diseases

CD19-CAR T-cell treatment is a novel option of deep B cell depletion with promising results across different rheumatologic and musculoskeletal diseases (RMD).

15 Jun 2025

Waters acquires Halo Labs, expanding biological analysis portfolio

Waters Corporation today announced that it has acquired Halo Labs™, an innovator of specialized imaging technologies to detect, identify, and count interfering materials (particles) in therapeutic products, such as cell, protein, and gene therapies.

From Waters Corporation 23 May 2025

New gene editor evoCAST enables precise insertion of complete genes

Ask scientists what gene editing tool is most needed to advance gene therapy, and they'd probably describe a system that's now close to realization in the labs of Samuel Sternberg at Columbia University Vagelos College of Physicians and Surgeons and David Liu at the Broad Institute of MIT and Harvard.

15 May 2025

Next-generation "armored" CAR T cell therapy shows promising results in lymphoma patients

A next-generation "armored" CAR T cell therapy showed promising results in a small study of patients whose B-cell lymphomas continued to resist multiple rounds of other cancer treatments, including commercially available CAR T cell therapies.

8 May 2025

New CAR T cell therapy shows promise for treating advanced thyroid cancer

A new chimeric antigen receptor (CAR) T cell therapy called AIC100, which targets the ICAM-1 protein, demonstrated encouraging responses and an acceptable safety profile in patients with two types of advanced thyroid cancer, according to researchers from The University of Texas MD Anderson Cancer Center.

29 Apr 2025

Survey reveals low awareness of innovative cancer treatment among Americans

Roswell Park Comprehensive Cancer Center is at the forefront of a new approach to cancer treatment, called CAR T-cell therapy.

17 Apr 2025

EchoBack CAR T-cells could be a game changer in cancer immunotherapy

Imagine a super-charged immune cell that can launch a focused attack on stubborn solid tumors - a smart fighter that destroys cancer cells for days without tiring.

2 Apr 2025

Cancer-free for 18 years: CAR-T therapy sets new milestone in neuroblastoma treatment

A groundbreaking study in Nature Medicine reveals that GD2 CAR-T cell therapy can lead to long-term remission in children with neuroblastoma, with one patient remaining cancer-free for over 18 years.

17 Feb 2025

The CAR T Veteran: A Journey of Resilience, Remission, and Advocacy

Laurie Adami's experience with CAR T-cell therapy highlights its potential in treating Non-Hodgkin Lymphoma, emphasizing the importance of patient advocacy.

3 Feb 2025

New therapeutic target could boost CAR T-cell therapy success in solid tumors

Russell W. Jenkins, MD, PhD, a physician investigator in the Krantz Family Center for Cancer Research at the Mass General Cancer Center and an assistant professor of Medicine at Harvard Medical School, is senior author of a new study in Cancer Immunology Research, "TBK1 is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids".

10 Jan 2025

Ultrasound-controlled CRISPR offers precision in treating genetic disorders

Thanks to CRISPR, our medical specialists will soon have unprecedented control over how they treat and prevent some of our most challenging genetic disorders and diseases.

4 Dec 2024

New study explores obecabtagene autoleucel for adults with hard-to-treat leukemia

FELIX study results reveal obe-cel's potential in relapsed B-cell ALL, achieving 77% remission with low severe toxicity, enhancing CAR T-cell therapy outcomes.

2 Dec 2024

IASLC and LCRF announce first grant recipient for lung cancer research

The International Association for the Study of Lung Cancer (IASLC) and The Lung Cancer Research Foundation (LCRF) announce the first grant recipient of the IASLC LCRF Team Science Research Grant on the Next Step in the Cure of Oncogene-Driven Lung Cancers Award.

25 Nov 2024

ESGCT Conference Takeaways: A specialty laboratory perspective

Discover the latest innovations in cell and gene therapy via Cerba Research's highlights of ESGCT.

From Cerba Research 22 Nov 2024

New CAR T-cell therapy shows promise against aggressive HER2+ breast cancer

One-third of HER2-positive (HER2+) tumors express the P95HER2 protein, which associates with an aggressive form of breast cancer with a poorer prognosis. Investigators of the Vall d'Hebron Institute of Oncology's (VHIO) Growth Factors Group, in collaboration with researchers of the Cancer Research Program of Hospital del Mar Research Institute (HMRI), Barcelona, have developed novel chimeric antigen receptor (CAR) T-cell therapy that can produce a potent antitumor response against p95HER2-expressing cells.

19 Nov 2024

Engineered SNIPRs transform CAR T-cell precision for safer cancer therapy

Researchers developed SNIPRs, innovative receptors that sense soluble ligands, enabling precise therapeutic control in CAR T-cells. This breakthrough enhances tumor targeting while reducing off-target effects, paving the way for advanced synthetic biology applications.

17 Nov 2024

Duke-NUS team develops test to monitor engineered T cells in cancer treatment

A novel test developed by Duke-NUS researchers enables real-time monitoring of T cells that have been engineered to fight cancer, after re-introduction into the body of a cancer patient.

15 Nov 2024

Customizable biological sensors activate cancer immunotherapy only in tumor environments

Most cancer treatments – from chemotherapies to engineered immune cells – have a host of side effects, in large part because they affect healthy cells in the body at the same time as targeting tumor cells.